Shares of Vernalis plc (LON:VER) have received a consensus rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is GBX 46.80 ($0.61).

Several equities research analysts have issued reports on the stock. Numis Securities Ltd assumed coverage on shares of Vernalis plc in a research report on Tuesday, April 4th. They issued an “add” rating and a GBX 29 ($0.38) price objective for the company. Stifel Nicolaus lowered their price objective on shares of Vernalis plc from GBX 31 ($0.40) to GBX 29 ($0.38) and set a “hold” rating for the company in a research report on Tuesday, April 4th. N+1 Singer reissued a “hold” rating and issued a GBX 28 ($0.36) price objective on shares of Vernalis plc in a research report on Friday, April 21st. Finally, Panmure Gordon cut shares of Vernalis plc to a “hold” rating and set a GBX 65 ($0.84) price objective for the company. in a research report on Friday, April 21st.

TRADEMARK VIOLATION WARNING: “Vernalis plc (LON:VER) Given Consensus Rating of “Hold” by Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/07/11/vernalis-plc-lonver-given-consensus-rating-of-hold-by-analysts.html.

Vernalis plc (LON:VER) traded down 2.70% during mid-day trading on Tuesday, hitting GBX 18.00. 434 shares of the stock were exchanged. The firm’s market capitalization is GBX 94.74 million. The company’s 50-day moving average price is GBX 17.97 and its 200 day moving average price is GBX 25.31. Vernalis plc has a 52 week low of GBX 16.00 and a 52 week high of GBX 49.75.

About Vernalis plc

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.